Dopamine D1-like receptor blockade and stimulation decreases operant responding for nicotine and food in male and female rats.

Tytuł:: Dopamine D1-like receptor blockade and stimulation decreases operant responding for nicotine and food in male and female rats.
Autorzy:: Chellian R; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Behnood-Rod A; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Wilson R; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Lin K; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
King GW; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Ruppert-Gomez M; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Teter AN; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Febo M; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA.
Bruijnzeel AW; Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA. .
Źródło:: Scientific reports [Sci Rep] 2022 Aug 19; Vol. 12 (1), pp. 14131. Date of Electronic Publication: 2022 Aug 19.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:: Dopamine*/pharmacology
Nicotine*/pharmacology
Animals ; Benzazepines ; Conditioning, Operant ; Dopamine Agonists/pharmacology ; Dopamine Antagonists/pharmacology ; Dose-Response Relationship, Drug ; Female ; Male ; Rats ; Receptors, Dopamine D1/agonists ; Smoking
References:: MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1108-12. (PMID: 25426653)
Psychopharmacology (Berl). 1997 Nov;134(2):187-92. (PMID: 9399383)
J Pharmacol Exp Ther. 1996 Mar;276(3):1022-9. (PMID: 8786531)
Psychopharmacology (Berl). 2002 Sep;163(2):194-201. (PMID: 12202966)
Psychopharmacology (Berl). 2007 Apr;191(3):719-30. (PMID: 16835769)
J Clin Invest. 2021 Sep 15;131(18):. (PMID: 34264865)
Psychopharmacology (Berl). 2010 Jul;211(1):43-54. (PMID: 20437028)
Neurosci Biobehav Rev. 2012 May;36(5):1418-41. (PMID: 22405889)
N Engl J Med. 2019 Oct 10;381(15):1490-1491. (PMID: 31532955)
Psychopharmacology (Berl). 2002 Jan;159(2):145-53. (PMID: 11862342)
Biol Psychiatry. 2007 Jun 1;61(11):1252-9. (PMID: 16945342)
J Pharmacol Exp Ther. 1994 Jul;270(1):209-18. (PMID: 8035317)
Pharmacol Biochem Behav. 2019 Nov;186:172766. (PMID: 31470021)
Synapse. 1994 Jan;16(1):36-44. (PMID: 8134899)
Pharmacol Biochem Behav. 2013 Dec;114-115:70-81. (PMID: 24201048)
Physiol Behav. 2019 May 1;203:42-50. (PMID: 29158125)
Lung Cancer. 2004 Aug;45 Suppl 2:S3-9. (PMID: 15552776)
Psychopharmacology (Berl). 2001 Apr;154(4):420-8. (PMID: 11349397)
Psychopharmacology (Berl). 1999 Apr;143(3):318-21. (PMID: 10353437)
Psychopharmacology (Berl). 1993;112(2-3):389-97. (PMID: 7871047)
Psychopharmacology (Berl). 1991;104(2):171-6. (PMID: 1876661)
Pharmacogenetics. 1996 Feb;6(1):73-9. (PMID: 8845863)
Psychopharmacology (Berl). 1996 May;125(2):162-7. (PMID: 8783390)
Pharmacol Biochem Behav. 2021 Aug;207:173224. (PMID: 34197844)
Neuropharmacology. 2015 Dec;99:689-95. (PMID: 25797492)
Eur J Pharmacol. 2006 Feb 27;532(3):253-7. (PMID: 16478622)
J Pharmacol Exp Ther. 1998 Jul;286(1):345-53. (PMID: 9655879)
Brain Res. 2000 Jan 3;852(1):198-207. (PMID: 10661513)
Lancet. 2011 Oct 8;378(9799):1297-305. (PMID: 21839503)
Pharmacol Biochem Behav. 2020 Sep;196:172998. (PMID: 32681850)
CNS Drug Rev. 2001 Winter;7(4):399-414. (PMID: 11830757)
Neurosci Biobehav Rev. 2006;30(2):215-38. (PMID: 16099045)
Eur J Pharmacol. 1991 Jul 23;200(1):89-93. (PMID: 1685124)
J Neurosci. 2014 Dec 10;34(50):16851-5. (PMID: 25505336)
Behav Brain Res. 2014 Nov 1;274:10-8. (PMID: 25101539)
J Neurosci. 2007 Nov 28;27(48):13140-50. (PMID: 18045908)
Annu Rev Pharmacol Toxicol. 2009;49:57-71. (PMID: 18834313)
Hum Genet. 2008 Mar;123(2):133-40. (PMID: 18092181)
N Engl J Med. 2010 Jun 17;362(24):2295-303. (PMID: 20554984)
Psychopharmacology (Berl). 1998 Mar;136(1):83-90. (PMID: 9537686)
Synapse. 2001 Oct;42(1):48-53. (PMID: 11668590)
Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):457-61. (PMID: 7667368)
Neuropharmacology. 2004 Sep;47(4):572-9. (PMID: 15380374)
Pharmacol Biochem Behav. 2009 Nov;94(1):43-50. (PMID: 19619575)
Nicotine Tob Res. 2020 May 26;22(6):925-934. (PMID: 31603225)
Clin Neuropharmacol. 2014 Jan-Feb;37(1):26-30. (PMID: 24434529)
Nicotine Tob Res. 2021 Nov 5;23(12):2117-2126. (PMID: 33987656)
Pharmacol Biochem Behav. 1985 Feb;22(2):341-2. (PMID: 2858871)
Neuron. 2020 Mar 4;105(5):909-920.e5. (PMID: 31879163)
Psychopharmacology (Berl). 1991;104(3):343-50. (PMID: 1833784)
Sci Rep. 2021 Dec 31;11(1):24529. (PMID: 34972820)
Brain Res. 2005 Feb 8;1033(2):179-85. (PMID: 15694922)
Ann N Y Acad Sci. 2000 Sep;914:13-21. (PMID: 11085304)
Psychopharmacology (Berl). 1987;92(3):343-9. (PMID: 2957718)
Psychopharmacology (Berl). 2005 Jul;180(2):258-66. (PMID: 15682294)
Nature. 2020 Apr;580(7802):239-244. (PMID: 32269346)
Drug Alcohol Depend. 2012 Mar 1;121(3):240-6. (PMID: 21945235)
Pharmacol Biochem Behav. 2007 Feb;86(2):297-305. (PMID: 17141304)
Nicotine Tob Res. 2020 Feb 6;22(2):172-179. (PMID: 30452710)
Eur J Pharmacol. 1992 Dec 15;229(2-3):203-9. (PMID: 1362704)
J Pharmacol Exp Ther. 1984 Sep;230(3):678-83. (PMID: 6332190)
Sci Rep. 2018 Dec 24;8(1):18069. (PMID: 30584246)
Nicotine Tob Res. 2001 May;3(2):141-50. (PMID: 11403728)
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3101-6. (PMID: 22308372)
Eur J Pharmacol. 1994 Jul 21;260(1):85-7. (PMID: 7957630)
Psychopharmacology (Berl). 2000 Sep;151(4):392-405. (PMID: 11026746)
Biol Psychiatry. 2001 Feb 1;49(3):258-67. (PMID: 11230877)
Pharmacol Biochem Behav. 2021 May;204:173168. (PMID: 33684454)
J Pharmacol Exp Ther. 2001 Feb;296(2):338-44. (PMID: 11160615)
Exp Clin Psychopharmacol. 2016 Jun;24(3):193-205. (PMID: 26987070)
Tob Use Insights. 2021 Dec 20;14:1179173X211067439. (PMID: 34987299)
Grant Information:: DA046411 United States DA NIDA NIH HHS
Substance Nomenclature:: 0 (Benzazepines)
0 (Dopamine Agonists)
0 (Dopamine Antagonists)
0 (Receptors, Dopamine D1)
6M3C89ZY6R (Nicotine)
VTD58H1Z2X (Dopamine)
Entry Date(s):: Date Created: 20220819 Date Completed: 20220823 Latest Revision: 20221026
Update Code:: 20240104
PubMed Central ID:: PMC9388990
DOI:: 10.1038/s41598-022-18081-3
PMID:: 35986048
: Czasopismo naukowe

Pełny tekst

Dopamine has been implicated in the reinforcing effects of smoking. However, there remains a need for a better understanding of the effects of dopamine D1-like receptor agonists on nicotine intake and the role of sex differences in the effects of dopaminergic drugs on behavior. This work studied the effects of D1-like receptor stimulation and blockade on operant responding for nicotine and food and locomotor activity in male and female rats. The effects of the D1-like receptor antagonist SCH 23390 (0.003, 0.01, 0.03 mg/kg) and the D1-like receptor agonist A77636 (0.1, 0.3, 1 mg/kg) on responding for nicotine and food, and locomotor activity were investigated. The effects of SCH 23390 were investigated 15 min and 24 h after treatment, and the effects of the long-acting drug A77636 were investigated 15 min, 24 h, and 48 h after treatment. Operant responding for nicotine and food and locomotor activity were decreased immediately after treatment with SCH 23390. Treatment with SCH 23390 did not have any long-term effects. Operant responding for nicotine was still decreased 48 h after treatment with A77636, and food responding was decreased up to 24 h after treatment. Treatment with A77636 only decreased locomotor activity at the 48 h time point. There were no sex differences in the effects of SCH 23390 or A77636. In conclusion, the D1-like receptor antagonist SCH 23390 reduces nicotine intake and causes sedation in rats. Stimulation of D1-like receptors with A77636 decreases nicotine intake at time points that the drug does not cause sedation.
(© 2022. The Author(s).)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja